low-dose CNS-penetrant BACE inhibitor
90% red. of CSF A_ in Ph. II at 9.2 mg / discont.
from opt. vs. CatD and dose red. of prior leads
Journal of Medicinal Chemistry
Eli Lilly, Indianapolis, US
LY3202626
6. The Lilly beta-site APP cleaving enzyme (BACE) inhibitor LY3202626 is an oral, low-dose, CNS-penetrant molecule which entered a Phase II of clinical trial against AlzheimerÕs disease in 2016.…